SCHEMBL5550842

SCHEMBL5550842

Cc1ccc(NC(N)=O)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.58
RAB9A P51151 3/20 0.58
NFKB1 P19838 2/20 0.58
TP53 P04637 1/20 0.58
MAPT P10636 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GAA P10253 1/20 0.48
PKM P14618 1/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
DAO P14920 1/20 0.42
RAF1 P04049 1/20 0.41
KIF11 P52732 1/20 0.41
ATF1 P18846 1/20 0.40
ALOX5 P09917 1/20 0.40
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1005754 0.83 NPC1 (0.67) NPC1RAB9ANFKB1TP53MAPT
SCHEMBL14584377 0.81 HSD17B10 (0.75) NPC1RAB9ANFKB1TP53MAPT
SCHEMBL11174292 0.79 NPC1 (0.58) NPC1RAB9ANFKB1TP53MAPT
SCHEMBL2705561 0.78 NFKB1 (0.61) NPC1RAB9ANFKB1TP53MAPT
SCHEMBL11455366 0.76 TP53 (0.54) NPC1RAB9ANFKB1TP53MAPT
SCHEMBL209971 0.76 NFKB1 (0.59) NPC1RAB9ANFKB1TP53MAPT
SCHEMBL7057048 0.75 GAA (0.43) NPC1RAB9AMAPTSMN1; SMN2GAA
SCHEMBL5554805 0.75 GAA (0.44) NPC1RAB9ATP53MAPTSMN1; SMN2
Lithium Ion SCHEMBL209972 0.75 NPC1 (0.53) NPC1RAB9ANFKB1TP53MAPT
SCHEMBL208477 0.75 NPC1 (0.53) NPC1RAB9ANFKB1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN disclosed
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors ASTRAZENECA AB (SE) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors CHEK1, CHKA, CHEK2 NPC1 543/4885RAB9A 2722/4885NFKB1 1747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.